Egypt’s national breast cancer screening program, the Presidential Initiative for Women’s Health, appears to deliver more health at lower cost than the routine, symptom-driven care it replaced, according to a model-based economic evaluation published in Archives of Public Health. The analysis draws on program data covering roughly 23.8 million unique women who generated more than 53 million recorded screening and service encounters between July 2019 and September 2024. But the authors are unusually explicit that their headline numbers are projections built on transferred survival and utility data, not directly observed survival gains, and that the finding should not be read as cash savings available for reallocation.
The initiative, launched in July 2019, offers free early detection, diagnosis and treatment services to women aged 18 and above across all Egyptian governorates. The entry point is deliberately not mammography: women first complete a risk assessment questionnaire and undergo clinical breast examination, with imaging reserved for those whose clinical assessment raises suspicion. That design reflects the younger age profile of breast cancer in Egypt, where the mean age at diagnosis is approximately 50.4 years and around 20 percent of patients are under 40. Mammography is less sensitive in dense breast tissue, which is more common in younger women, so the program follows an early-diagnosis model closer to the World Health Organization’s framework for symptomatic women than a population mammography program.
The scale of the program is substantial. Of the 53,453,745 recorded encounters, 34.6 million progressed to primary care unit examination, and the diagnostic cascade eventually produced 30,225 pathologically confirmed breast cancer cases. Because women could re-attend, the encounter counts are not person-level detection rates, a distinction the authors take care to draw. They also distinguish their figures from later public reports of roughly 70 million services and visits as of October 2025, which use a broader service definition over a longer period and should not be interpreted as 70 million unique women screened.
The most striking observed difference lies in the stage at which cancers were diagnosed. In the initiative data, 61.3 percent of confirmed cases were detected at stage I or II, compared with 41.6 percent in a comparator dataset drawn from Ministry of Health records of cases diagnosed outside the organized program. The proportion of stage III or IV diagnoses was 38.7 percent in the initiative data versus 58.5 percent in the comparator, an absolute gap of 19.8 percentage points. The authors caution that this is an observed difference in stage distribution, not by itself evidence that screening caused a reduction in mortality.
To translate that stage shift into health and economic outcomes, the researchers built a hybrid decision tree and Markov model comparing the initiative pathway with opportunistic case detection over a lifetime horizon, from a societal perspective. The model simulated a cohort entering at age 45 and followed for 28 cycles, approximating female life expectancy in Egypt. Because no Egyptian stage-specific survival series compatible with the model’s health states could be identified, survival rates were taken from English NHS cancer statistics for diagnoses between 2016 and 2020. Utility values came from a published study of 156 women not receiving active breast cancer treatment, mapped directly onto the four disease stages.
Under base-case assumptions, the model estimated 32,576 incremental quality-adjusted life years and 63,448 additional discounted life years for the initiative arm, alongside total societal costs of EGP 11.68 billion (about USD 258 million) versus EGP 18.07 billion (about USD 398 million) in the comparator. That yields a net societal saving of EGP 6.39 billion (about USD 141 million) and a return on investment of 54.7 percent. The savings arise because earlier-stage disease is cheaper to treat: the incremental direct medical cost saving was EGP 5.77 billion, despite the initiative’s additional screening and diagnostic investment of roughly EGP 1.13 billion, with averted productivity losses from premature death adding a further EGP 620 million.
Uncertainty analysis reinforced the direction of the finding. In a one-way deterministic sensitivity analysis, the return on investment ranged from roughly 43.5 to 70.4 percent across tested parameter ranges, with the result most sensitive to the number of confirmed cases, total screening costs and the stage IV mortality rate. A 5,000-iteration Monte Carlo probabilistic sensitivity analysis found the initiative dominant, meaning both less costly and more effective, in 99.76 percent of simulations, and cost-effective at the Egyptian threshold of EGP 164,588 per quality-adjusted life year in all 5,000 simulations. The base-case net monetary benefit at that threshold was EGP 11.75 billion, with a simulation mean of EGP 11.85 billion.
The limitations are considerable and the authors enumerate them candidly. Lead-time bias, length bias and overdiagnosis may make screen-detected outcomes appear more favorable without a proportional mortality benefit, and no overdiagnosis correction was applied. The model includes breast cancer-related death only, omitting background all-cause mortality, remission and recurrence states, and a separate state for ductal carcinoma in situ. No disutilities were applied for screening participation, false-positive recall or treatment adverse events. Direct non-medical costs, informal caregiver time and morbidity-related productivity losses were excluded, making the perspective partial rather than fully societal. Cost inputs spanning the five-year period were not fully rebased to a common price year despite substantial Egyptian inflation, so nominal totals should not be read as constant-price quantities.
The authors also contextualize the observed early-stage rate within the program’s evolution. An earlier publication covering the first two years, when the program operated primarily as a walk-in community screening service, documented that 80.5 percent of screen-detected cancers were diagnosed at clinical stage 0 to II. That cohort was inherently enriched for symptomatic or health-seeking women. As the initiative expanded into a comprehensive national program, previously diagnosed patients and those detected through broader referral pathways were integrated into the database, attenuating the early-stage proportion to roughly 61 percent. The authors argue this reflects increasing inclusivity rather than deteriorating performance, and note the rate remains well above the background opportunistic detection rate of about 41.6 percent.
Against the WHO Global Breast Cancer Initiative target that at least 60 percent of invasive breast cancers be diagnosed at stage I or II, the 61.3 percent figure nominally meets the benchmark, though the authors describe the comparison as indicative rather than exact because the program denominator excludes cancers diagnosed outside the initiative. They conclude that continued investment, optimization of follow-up pathways and expanded outreach are warranted, alongside collection of Egyptian long-term outcome data to validate the model’s projections. Notably, the diagnostic cascade revealed sizable attrition at the tertiary referral stage, with only 57.6 percent of women referred to tertiary care units actually attending, a bottleneck the authors flag as requiring dedicated investigation before specific interventions can be recommended.
Subject of Research: Economic evaluation of Egypt's Presidential Initiative for nationwide breast cancer early detection and treatment
Article Title: Advancing women’s health in Egypt: an economic evaluation of the presidential initiative for nationwide breast cancer early detection and treatment
Article References: Abdelghaffar, K., Hassany, M., Elghazaly, H., Amin, H., Morsi, A., Shash, E., Abdelaziz, A. H., Kassem, L., Omar, N., Shaltout, D., Mostafa, S. M., Ashraf, A., Awad, M. A. B., Bendary, R. E., Khalil, H., Gazar, S., Atef, B., Ibrahim, A., & Anan, I. (2026). Advancing women’s health in Egypt: an economic evaluation of the presidential initiative for nationwide breast cancer early detection and treatment. Archives of Public Health, 84(1), Article 228. https://doi.org/10.1186/s13690-026-02122-8
Image Credits: AI Generated
DOI: 10.1186/s13690-026-02122-8
Keywords: breast cancer, Egypt, screening, health economics, cost-effectiveness, Markov model, early detection, QALYs, return on investment, stage shift, public health, women's health
News Source: Nathaniel Bowman. (October 28, 2026). Egypt’s free breast cancer screening program saves money, model finds, with caveats attached. Scienmag.
